voglibose 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antihyperglycaemics	2845	83480-29-9

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

voglibose
glustat
voglistat
AO-128

Molecular weight: 267.28
Formula: C10H21NO7
CLOGP: -0.93
LIPINSKI: 1
HAC: 8
HDO: 8
TPSA: 153.64
ALOGS: -0.15
ROTB: 5

Drug dosage:

Dose	Unit	Route
0.60	mg	O

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	6 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Aug. 20, 1994	PMDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypoglycaemia	111.68	32.65	43	1259	60022	63427698
Pneumatosis intestinalis	76.61	32.65	16	1286	2397	63485323
Renal impairment	62.05	32.65	32	1270	88323	63399397
Lactic acidosis	48.96	32.65	21	1281	38266	63449454
Cerebral infarction	43.89	32.65	17	1285	23876	63463844
Hepatic function abnormal	39.80	32.65	18	1284	37124	63450596

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cerebral infarction	96.04	25.08	41	1893	27414	34927583
Interstitial lung disease	70.04	25.08	44	1890	65238	34889759
Hypoglycaemia	69.30	25.08	41	1893	54599	34900398
Pneumatosis intestinalis	48.81	25.08	15	1919	3908	34951089
Pemphigoid	37.18	25.08	15	1919	8651	34946346
Thrombotic cerebral infarction	27.95	25.08	6	1928	374	34954623
Renal impairment	26.06	25.08	29	1905	94484	34860513

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypoglycaemia	163.35	26.00	83	3492	101511	79639302
Cerebral infarction	135.07	26.00	57	3518	45619	79695194
Pneumatosis intestinalis	100.67	26.00	28	3547	6369	79734444
Interstitial lung disease	76.99	26.00	53	3522	112547	79628266
Renal impairment	75.75	26.00	60	3515	157723	79583090
Hepatic function abnormal	53.70	26.00	36	3539	73071	79667742
Pemphigoid	44.82	26.00	19	3556	15296	79725517
Lactic acidosis	43.11	26.00	31	3544	70328	79670485
Platelet count decreased	39.39	26.00	46	3529	194618	79546195
Thrombotic cerebral infarction	37.98	26.00	8	3567	564	79740249
Diabetes mellitus inadequate control	36.48	26.00	19	3556	24245	79716568
Ketoacidosis	34.29	26.00	13	3562	7841	79732972
Altered state of consciousness	33.17	26.00	22	3553	43800	79697013
Hypoglycaemic coma	32.60	26.00	11	3564	4749	79736064
Diabetes mellitus	31.65	26.00	27	3548	78363	79662450
Liver disorder	31.41	26.00	26	3549	72391	79668422
Cerebral haemorrhage	27.74	26.00	22	3553	57651	79683162
Drug eruption	26.08	26.00	19	3556	43916	79696897

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A10BF03	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Alpha glucosidase inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D065089	Glycoside Hydrolase Inhibitors
MeSH PA	D007004	Hypoglycemic Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Diabetes mellitus type 2	indication	44054006	DOID:9352
Glucosylceramide beta-glucosidase deficiency	indication	190794006	DOID:1926
Impaired renal function disorder	contraindication	197663003
Pregnancy, function	contraindication	289908002
Peripheral nerve disease	contraindication	302226006
Breastfeeding (mother)	contraindication	413712001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.5	acidic
pKa2	12.5	acidic
pKa3	8.5	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Lysosomal alpha-glucosidase	Enzyme	P10253	LYAG_HUMAN	INHIBITOR	IC50	7.15		CHEMBL	SCIENTIFIC LITERATURE
Maltase-glucoamylase, intestinal	Enzyme	O43451	MGA_HUMAN		IC50	5.89		CHEMBL
Sucrase-isomaltase, intestinal	Enzyme		SUIS_RAT		IC50	7.15		CHEMBL
Lysosomal alpha-glucosidase	Enzyme		LYAG_RAT		IC50	6.96		CHEMBL
Glycogen debranching enzyme	Enzyme		GDE_RABIT		IC50	4.15		CHEMBL

External reference:

ID	Source
D01665	KEGG_DRUG
C0532578	UMLSCUI
CHEBI:32300	CHEBI
VOG	PDB_CHEM_ID
CHEMBL476960	ChEMBL_ID
DB04878	DRUGBANK_ID
C102817	MESH_SUPPLEMENTAL_RECORD_UI
444020	PUBCHEM_CID
C054577	MESH_SUPPLEMENTAL_RECORD_UI
6797	INN_ID
S77P977AG8	UNII
010940	NDDF
1163442006	SNOMEDCT_US
1172848007	SNOMEDCT_US

Pharmaceutical products:

None